Nkarta

Nkarta is advancing a new class of cell therapies using engineered natural killer (NK) cells to target and destroy cancer. The company's core technology focuses on developing allogeneic, or 'off-the-shelf,' cell therapies from healthy donor cells, which are engineered with chimeric antigen receptors (CARs) and membrane-bound cytokines to enhance their anti-tumor activity. Key milestones include advancing its lead candidates, NKX101 and NKX019, into clinical trials for hematologic cancers and solid tumors, supported by strategic partnerships and public market funding. Nkarta aims to overcome the limitations of autologous CAR-T therapies by creating readily available, potent, and scalable NK cell products.

Proprietary platform for expanding and engineering allogeneic natural killer (NK) cells from healthy donors, incorporating chimeric antigen receptors (CARs) and membrane-bound cytokines to create off-the-shelf cell therapies for cancer.

4 drugs in pipeline

Total raised: $414M

Nkarta competes with autologous CAR-T leaders (Gilead, BMS) and allogeneic cell therapy companies like Allogene Therapeutics and Fate Therapeutics. Its differentiation lies in its engineered primary NK cell platform with membrane-bound IL-15, targeting both hematologic and solid tumors.